E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Organ Dysfunction and Failure in Traumatic Hemorrhage |
|
E.1.1.1 | Medical condition in easily understood language |
Organ failure following severe injury-induced critical bleeding |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Injuries, poisonings, and occupational diseases [C21] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine whether Artesunate is safe and effective in treating severely-injured patients with traumatic haemorrhage in addition to the current standard management.
|
|
E.2.2 | Secondary objectives of the trial |
We have discovered that when administered at small doses upon resuscitation, the anti-malarial drug Artesunate reduces multiple organ failure in rodent models of traumatic hemorrhage. We now wish to conduct a Phase 2a clinical trial aimed at testing the safety and effectiveness of Artesunate in patients with trauma and severe haemorrhage.
In the first phase of the study, we wish to administer Artesunate to patients with trauma-haemorrhage at an identical dose to that used for the treatment of malaria (i.e. low dose; 2.4mg/kg). Although in malaria Artesunate is repeatedly administered every 12 hrs, we propose to inject only one dose. Provided an interim analysis demonstrates no concerns with safety of Artesunate, we will proceed to administer a higher dose of Artesunate (i.e. 4.8 mg/kg) to examine whether the higher dose is more effective in improving outcomes following trauma haemorrhage, whilst still being safe to give to patients.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
A patient will be eligible for the study if they meet the following criteria;
• Adult trauma patients • Activation of the local massive haemorrhage protocol • Patients with active, ongoing haemorrhage
|
|
E.4 | Principal exclusion criteria |
The principle exclusion critieria include:
• Patients not expected to survive >48 hours • Patients with evidence of severe traumatic brain injury (GCS 3 at scene) • Known pregnancy • Suspected non-haemorrhagic cause of shock • Massive haemorrhage protocol activation >1 hour after arrival • IMP administration not attainable within 4 hours of injury • Admission greater than 2 hours post injury • Breastfeeding |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Sequential Organ Failure Score (SOFA) at 48 hours |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Maximum SOFA score (Admission to day 7) • Prolonged organ failure (SOFA>5 on day 7) • Total length of hospital stay (days) • Days on organ support (CTCOFR score to discharge, 28-day) • Total critical care stay (days) • Ventilator free days at Day 28 (days) • Incidence of acute lung injury (to discharge, 28-day) • Incidence of acute kidney injury (to discharge, 28-day) • Incidence of infection (to discharge, 28-day) • Mortality (Discharge, 28-day and 90-day)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study will be considered to be closed when all surviving participants have completed in-hospital safety and outcomes monitoring (including Mortality at discharge, 28-day and 90-day). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |